Displaying 1 - 63 of 63 results
Showing 1 - 63 of 63 results
-
Partners beginning with A
-
-
accuRx
-
Stages:that accuRx support
- Venture Growth
-
Sector:that accuRx support
- Technology
About accuRx
accuRx is one of the UK’s fastest-growing healthtech startups, building a communication platform to join up all healthcare communication around the patient to help the NHS deliver more informed care. Founded in 2016, its mission is to change lives by bringing patients and their healthcare teams together. It allows existing health and care systems to deliver technology-enabled care, beginning with the National Health Service (NHS) in the UK. accuRx’s vision is that anyone involved in a patient’s care can communicate with each other. accuRx is now used by 98% of GP practices and a number of secondary care providers.
-
-
-
Abingworth
-
Stages:that Abingworth support
- Venture
-
Sector:that Abingworth support
- Life Sciences
About Abingworth
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in 170 life science companies, leading to 44 M&As and 69 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston.
-
-
-
Active Partners
-
Stages:that Active Partners support
- Venture Growth
About Active Partners
Founded in 2004, Active Partners invests in world-class consumer brands, partnering with passionate, innovative founders to build iconic global businesses. Active Partners takes a specialist approach to funding authentic challenger and high-growth sub-sector brands. The firm has invested in a number of hugely successful businesses, including Caravan, CHIK’N, Context, Cubitts, Evans Cycles, Finisterre, The Fold, Honest Burgers, LEON, Northern Monk, Rapha, Secret Cinema, Soho House, Taylor & Hart, TravelLocal and WhoCanFixMyCar.com. For more information, visit the Active Partners website at https://active.partners/
-
-
-
Advent Life Sciences
-
Stages:that Advent Life Sciences support
- Venture
-
Sector:that Advent Life Sciences support
- Life Sciences
About Advent Life Sciences
Advent Life Sciences founds and invests in early- and mid-stage life sciences companies that have a first- or best-in-class approach to unmet medical needs. The investing team consists of experienced professionals, each with extensive scientific, medical and operational experience, a long-standing record of entrepreneurial and investment success in the US and Europe and is particularly focused on supporting entrepreneurs and founders to take innovative new medical entities from concept to approval. The firm invests in a range of sectors within life sciences, principally drug discovery, enabling technologies and med tech, always with an emphasis on innovative, paradigm-changing approaches. Advent Life Sciences has a presence in the UK, US and France. For more information, please visit adventls.com
-
-
-
Alpina Partners
-
Stages:that Alpina Partners support
- Venture
-
Sector:that Alpina Partners support
- Consumer Goods & Services
- Technology
-
-
-
Amadeus Capital
-
Stages:that Amadeus Capital support
- Venture Growth
-
Sector:that Amadeus Capital support
- Agriculture, Forestry and Fishing
- Health & Social Care
- Information and Communication
- Professional, Scientific and Technical Activities
- Technology
About Amadeus Capital Partners
Amadeus Capital Partners is a global technology investor. Since 1997, the firm has raised over $1bn for investment and used it to back over 170 companies. With vast experience and a great network, Amadeus’ team of investors and entrepreneurs share a passion for the transformative power of technology.
Pioneering businesses we’ve backed include cyber security vendor ForeScout (NASDAQ:FSCT); Graphcore, innovators in intelligent microprocessors; IVF genetic testing company, Igenomix; the first single-chip Bluetooth solution, CSR (acquired by Qualcomm); IndiaMART, the B2B online marketplace (NSE: INDIAMART) and speech recognition company VocalIQ (acquired by Apple).
-
-
-
Atlantic Bridge
-
Stages:that Atlantic Bridge support
- Venture
-
Sector:that Atlantic Bridge support
- Information and Communication
- Technology
About Atlantic Bridge
Atlantic Bridge Capital is a Global Technology Fund with over €400 million of assets under management across four Funds, investing in technology companies in Europe. We have offices and staff based in London, Dublin, Silicon Valley, Beijing & Hong Kong.
The Fund is focused on investing primarily at the expansion capital and growth equity stages in companies that have started to scale in revenues with a proven business model with evidence of market uptake and customer adoption. Atlantic Bridge has developed a unique and differentiated strategy which focuses on specific technology themes and the implementation of the “Atlantic Bridge Model” for scaling companies internationally. The “Bridge Model” accelerates the scale up of technology companies in the US and Chinese markets. This approach is highly differentiated and has delivered strong performance results to date. The team has a thirty year operating history working together in technology as entrepreneurs and investors with over $7 billion in exits, having raised four successful technology funds.
-
-
-
Atomico
-
Stages:that Atomico support
- Venture
-
Sector:that Atomico support
- Other
About Atomico
Atomico is a London based venture capital firm partnering with ambitious mission driven European founders at Series A and beyond, leveraging deep operational experience to supercharge their growth. Founded in 2006, Atomico has partnered with over 100 ambitious teams – including those at Supercell, Graphcore, Omio, Klarna, Lilium, MessageBird, Gympass and The Climate Corporation. Atomico’s team of founders, investors and operational leaders have been responsible for global expansion, hiring and marketing at companies from Skype, Google and Twitter to Uber and Spotify. The firm currently has $2.7B in assets under management.
-
-
-
Partners beginning with B
-
-
Balderton Capital
-
Stages:that Balderton Capital support
- Venture
-
Sector:that Balderton Capital support
- Technology
About Balderton Capital
Balderton Capital is Europe’s largest early stage venture capital investor, focused on European technology companies at Series A. Based in London, the firm manages $2.6bn and invests in entrepreneurs building globally ambitious businesses. Balderton’s Partners and advisory team include the founders and operational leaders of multi-billion dollar companies including Business Objects, Dropbox, Uber and Autonomy. Previous investments include Betfair (FTSE: BET), Magic Pony (Twitter), NaturalMotion (Zynga), Sunrise (Microsoft) and Yoox Net-a-Porter (BIT: YNAP). Among Balderton’s current portfolio of 76 companies are: Aircall, Carwow, Citymapper, Contentful, GoCardless, The Hut Group, Kobalt Music, Nutmeg, Prodigy Finance, Recorded Future, Revolut, ROLI, SOPHiA Genetics, Talend (NASDAQ: TLND), Vestiaire Collective, and Vivino. For more see balderton.com or follow @balderton.
This year the firm has looked at more than 2,000 startups, from which it has made 10 investments in five countries since March, including Luno, Hiya and SOPHiA Genetics. Balderton’s previous fund (Fund V) has seen a range of category leaders such as Nutmeg, Revolut, Prodigy Finance, Aircall, Carwow, and Frontier Car Group emerge.
A small team with entrepreneurial roots, Balderton’s partners have between them founded companies that went on to become multi-billion dollar businesses, and worked in the engine rooms of some of the world’s best-known tech brands – including Uber and Dropbox. They have backgrounds and deep networks in Silicon Valley and beyond, and have returned to Europe to play their part in building businesses which will fuel economic growth, jobs and opportunity.
-
-
-
Partners beginning with C
-
-
Cambridge Innovation Capital
-
Stages:that Cambridge Innovation Capital support
- Venture
-
Sector:that Cambridge Innovation Capital support
- Life Sciences
- Technology
About Cambridge Innovation Capital
Cambridge Innovation Capital (CIC) is a leading venture investor backing and building category-leading deep tech and life sciences companies. CIC currently manages in excess of £0.5 billion and has invested in around 40 companies. CIC is a preferred investor for the University of Cambridge, Europe’s top source of founders for venture-backed start-ups.
Cambridge Innovation Capital Manager Limited (FRN:918898) is authorised and regulated by the Financial Conduct Authority. For more information, please visit www.cic.vc or follow on Twitter at @CIC_vc and LinkedIn.
-
-
-
CloudNC
-
Stages:that CloudNC support
- Venture Growth
-
Sector:that CloudNC support
- Technology
About CloudNC
CloudNC develops advanced software, tested and developed in its own facility, that enables factories to autonomously manufacture more products, more reliably, faster, and with less waste than current processes. The company is seeking to democratise production through its unique, full-stack factory in Essex, United Kingdom, where the software is continuously iterated to achieve full manufacturing autonomy. The company, founded in 2015, consists of a world-class team combining expertise in computer science and physical manufacturing, alongside Autodesk and Lockheed Martin as strategic partners helping to make CloudNC’s solutions available to factories around the world as a software product.
-
-
-
Connect Ventures
-
Sector:that Connect Ventures support
- Technology
About Connect Ventures
Connect Ventures is a thesis-led venture capital firm based in London and investing across Europe. We lead seed investments in purpose-led founders obsessed with solving hard problems at scale by creating products and companies that people love.
Our thesis is that in both B2B and consumer software companies, product and user experience are critical to building category leaders. We look for founders with global ambitions who put product and user experience at the centre of what they do.
Established in 2012, Connect is led by its three General Partners, Pietro Bezza, Rory Stirling and Sitar Teli. Connect has backed over 50 startups from a range of industries across both B2B and consumer software. Our current portfolio includes Citymapper, Typeform, Soldo, Truelayer, Curve, Kheiron and Fiit.
-
-
-
Crane
-
Stages:that Crane support
- Venture
-
Sector:that Crane support
- Technology
About Crane Venture Partners
Crane Venture Partners was founded in 2015 and raised $90 million for its first fund in 2019 and $140 million in its second fund in 2022. The firm focuses on early-stage founders building the platforms and tools that will become tomorrow’s software infrastructure across industries.
Crane’s partners work as extended members of founders’ teams, particularly in the areas of marketing, sales and customer success. With more than 50 focused portfolio companies, Crane is one of the deepest specialist funds in Europe. For more information, please visit: https://crane.vc/
-
-
-
CyberSmart
-
Stages:that CyberSmart support
- Venture Growth
-
Sector:that CyberSmart support
- Technology
About CyberSmart
Cybercrime is projected to cost the world $10.5 trillion annually by the end of 2025, and 58% targets small businesses. Meanwhile, the cybersecurity gap between large enterprises with the resources to weather attacks and the SMEs who don’t, is widening.
CyberSmart was created to fix this problem. Protecting a business from cyber threats shouldn’t require expert knowledge or deep pockets. So, as well as offering the fastest route to government grade certification on the market, CyberSmart also provides simple, cost-effective technology, enabling SMEs to protect themselves without cyber expertise. Through strategic partnerships with reputable insurers, CyberSmart customers further benefit from cyber insurance coverage at reduced premiums and policy excesses.
For more information, please visit cybersmart.co.uk.
-
-
-
Partners beginning with D
-
-
Dawn Capital
-
Stages:that Dawn Capital support
- Venture Growth
About Dawn
Dawn Capital (“Dawn”) is the largest VC fund dedicated to B2B software and B2B fintech start-ups across Europe. Dawn invests from Series A onwards, backing companies that develop world-leading offerings with unbeatable economics. Currently investing out of its third fund of $235 million, Dawn offers ambitious founders operational and financial support to deliver exceptional value growth. Dawn portfolio companies include Mimecast (NASDAQ: MIME with $2.7 market cap), iZettle (sold to PayPal for $2.2BN cash), Collibra, Showpad, Dataiku, Templafy, Quantexa and Garrison, with many others looking to join their ranks.
-
-
-
Dementia Discovery Fund
-
Stages:that Dementia Discovery Fund support
- Venture
-
Sector:that Dementia Discovery Fund support
- Health & Social Care
- Life Sciences
-
-
-
Partners beginning with E
-
-
Earlybird Venture Capital
-
Sector:that Earlybird Venture Capital support
- Health & Social Care
- Life Sciences
About Earlybird Venture Capital
Founded in 1997, Earlybird Venture Capital invests out of a family of independently managed funds, including flagship funds Digital West (Western Europe), Digital East (Emerging Europe), and Health. With EUR 2 billion under management across all fund streams, 9 IPOs, and 32 trade sales, Earlybird is one of Europe’s most established and active venture capital firms.
Earlybird Health employs a technology-agnostic approach, investing in opportunities across various healthcare sectors, including digital health, diagnostics, medical devices, R&D tools, and biopharma, with robust and positive patient outcomes.
-
-
-
Episode1 Ventures
About Episode 1
Episode 1 is a VC fund formed by a team of entrepreneurs, operators and technologists with over 20 years of experience in the 0-1 journey, investing in B2B software companies at Pre-Seed and Seed. The team has invested in notable companies such as Zoopla, Huboo, Carwow, Omnipresent, Betfair, Shazam and Raft.
-
-
Epsilogen
-
Stages:that Epsilogen support
- Venture Growth
-
Sector:that Epsilogen support
- Life Sciences
About Epsilogen
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defense against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity also seen. The company is also developing a proprietary IGEGTM antibody platform combining elements from both IgE and IgG antibodies into novel and proprietary antibody molecules with enhanced functionality.
Epsilogen began operations in 2017 as a spin out of King’s College London utilising the world class IgE expertise of Professor Sophia Karagiannis. Initial capital was provided by founding investor Epidarex Capital.
-
-
-
ETF Partners
-
Stages:that ETF Partners support
- Venture Growth
-
Sector:that ETF Partners support
- Technology
About ETF Partners
ETF Partners supports talented entrepreneurs and management teams with investment capital and experience. Our funds come from institutional investors, global corporations and family offices. We create value by investing in technology companies that make a difference. We call it ‘sustainability through innovation’.
For more insight into ETF Partners’ view on Sustainability through Innovation, please read our investor briefings.
-
-
-
Eurazeo
-
Stages:that Eurazeo support
- Venture
-
Sector:that Eurazeo support
- Consumer Goods & Services
- Financial and Insurance Services
- Life Sciences
- Technology
-
-
-
Evolution Equity Partners
-
Stages:that Evolution Equity Partners support
- Venture Growth
-
Sector:that Evolution Equity Partners support
- Technology
About Evolution Equity
Evolution Equity Partners, based in London, Palo Alto, New York City and Zurich invests in fast growing technology companies in North America and Europe helping exceptional entrepreneurs develop market leading companies. The firm has a focus on Cybersecurity and Enterprise Software and its partners have been involved as founders, investors and as senior operating executives in leading software companies around the world.
For more information, please visit www.evolutionequity.com or connect with on LinkedIn and Twitter @evolutionequity. -
-
-
Partners beginning with F
-
-
Finch Capital
-
Sector:that Finch Capital support
- Financial and Insurance Services
- Health & Social Care
- Real Estate Activities
About Finch Capital
Finch Capital is a thematic growth investor in high growth technology companies disrupting the world of financial, real estate and health run by exceptional entrepreneurs. Its mission is to fund and support the best entrepreneurs creating products that will shape the future of the themes they invest in. Finch leverages it international network and industry expertise to enable their portfolio companies to grow into leaders in their field. More information can be found on the Finch Capital website.
-
-
-
FPE Capital
-
Stages:that FPE Capital support
- Venture Growth
-
Sector:that FPE Capital support
- Technology
About FPE Capital
FPE is a growth private equity investor specialising in lower mid-market UK based companies with advantaged business models that offer significant growth potential in large markets that are undergoing structural change. FPE was established as an independent investor by its management team in March 2016. It is authorised and regulated by the Financial Conduct Authority.
-
-
-
Frog Capital
-
Stages:that Frog Capital support
- Venture Growth
-
Sector:that Frog Capital support
- Technology
About Frog Capital
Frog Capital is a London-based European investment firm, specialising in growth capital for technology-driven businesses. With a highly focused and selective approach, Frog leads or partners on investments of up to €20m to back ambitious teams that are scaling high-growth businesses with proven models.
Having had three successful exits from its Frog Capital I fund, Frog Capital has raised Frog Capital II from a mix of 14 institutional and family office investors.
-
-
-
Partners beginning with G
-
-
Grey Wolf Therapeutics
-
Stages:that Grey Wolf Therapeutics support
- Venture
-
Sector:that Grey Wolf Therapeutics support
- Life Sciences
About Grey Wolf Therapeutics
Greywolf Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology which controls T cells to guide the immune system. Greywolf's technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. The company is progressing first-in-class treatments to improve the lives of people with cancers, autoimmune disorders, and infectious diseases.
Greywolf's lead antigen modulator (GWRD5769) delivered strong results during a phase 1/2 trial in oncology, demonstrating proof-of-mechanism and target engagement, while the company's second (GRWD0715) is accelerating through preclinical development as a potential treatment within autoimmunity.
Greywolf is headquartered in Oxford, UK.
-
-
-
Partners beginning with H
-
-
Hoxton Ventures
-
Stages:that Hoxton Ventures support
- Venture
-
Sector:that Hoxton Ventures support
- Technology
About Hoxton Ventures
Hoxton Ventures is an early stage venture capital firm investing in European technology startups that can scale into large, global winners. It focuses on startups that either disrupt existing industries or invent entirely new market categories. It was an early investor in Babylon Health, Darktrace and Deliveroo, and its portfolio companies have grown to an aggregate value of over $7 billion. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed and Series A stage companies, and follows its capital through the life of the company. For more information please visit www.hoxtonventures.com.
-
-
-
Partners beginning with I
-
-
Iceotope
-
Stages:that Iceotope support
- Venture Growth
-
Sector:that Iceotope support
- Technology
About Iceotope
Iceotope’s chassis level precision immersion cooling solutions are engineered to cool the whole IT stack, in every use case, from Hyperscale to the Extreme Edge. By removing the need for fans and air-cooling infrastructure, Iceotope’s technologies operate in near silence — bringing game-changing reduction in energy and water consumption, and significant cost reductions in the design, build and operation of data centres and HPC solutions. For more information, visit: www.iceotope.com
-
-
-
IQ Capital
-
Stages:that IQ Capital support
- Venture
-
Sector:that IQ Capital support
- Technology
About IQ Capital Partners
IQ Capital Partners is an Early Growth Venture Capital firm established to address certain imbalances in the traditional European venture capital model, and focuses on creating a strong and effective collaboration with CEOs and other investors.
Our approach creates a solid collaboration with founders and other investors through the model of investing alongside sector experts and entrepreneurs – ‘ IQ Angels’ – who have previously managed and achieved significant exit success with innovative technology companies. These IQ Angels, endorsed by the portfolio companies, work in partnership with IQ Capital Partners and the company founders to provide connections and constructive strategic advice throughout the various growth phase hurdles and to provide a great sounding board for CEOs through open discussion and sharing of their previous experiences.
The fund invests between £1-5m in innovative, fast-growing technology and B2B companies, including SaaS and PaaS, IoT, digital media, enterprise software, robotics and med-tech. The team, Max Bautin, Ed Stacey and Kerry Baldwin, has delivered significant returns to investors since 1997, including Autonomy (IPO), Sirigen (BD), Phonetic Arts (Google), KVS (Veritas), JCP (Sun), 365Corp (IPO) and WhereonEarth (Yahoo) and draws upon a diverse range of investment experience to generate excellent returns to investors.
We are always open to building relationships with new ‘IQ Angels’ who have a deep understanding of a specific technology sector, gained through the experience of growing and exiting successful businesses in that sector, who are prepared to invest in early growth technology companies, and also prepared to take an active role and a collaborative approach. IQ Capital invests across the UK and has offices located in Cambridge and London.
-
-
-
Partners beginning with K
-
-
Kennet
-
Stages:that Kennet support
- Venture Growth
-
Sector:that Kennet support
- Technology
About Kennet Partners
Kennet is a leading international growth equity firm that invests in high-growth companies in Europe and North America. With offices in London and Silicon Valley, the firm supports entrepreneurial technology businesses with expansion capital to accelerate growth and build exceptional shareholder value. Kennet is an experienced investor with approximately $1 billion of cumulative funds under management.
-
-
-
Kester Capital
-
Stages:that Kester Capital support
- Venture
-
Sector:that Kester Capital support
- Consumer Goods & Services
- Financial and Insurance Services
- Health & Social Care
- Information and Communication
- Technology
-
-
-
Kindred
-
Stages:that Kindred support
- Venture
-
Sector:that Kindred support
- Technology
About Kindred Capital
Kindred Capital has £161m under management. It recently raised a £81m second fund and has finished making initial investments from its first fund, which was £80m. Kindred Capital is a seed and early stage venture capital investor, focusing on European technology companies. Based in London, invests in entrepreneurs building globally ambitious businesses.
Kindred’s portfolio includes Five, Paddle, LabGenius, Pollen, Disperse and Farewill. Kindred’s Equitable Venture model is currently predicted to return over £5m to portfolio founders.
-
-
-
Partners beginning with M
-
-
Microbiotica
-
Stages:that Microbiotica support
- Venture
-
Sector:that Microbiotica support
- Life Sciences
About Microbiotica
Microbiotica is a leading player in the field of microbiome-based therapeutics, biomarkers and targets. The Company is building a growing pipeline of differentiated products based on high quality clinical datasets and unique bacterial signatures that drive biology, identified by its proprietary platform.
Consisting of the leading microbiome Reference Genome Database, Culture Collection, mass culturing technology (Personalised Bacterial Bank) and proprietary AI tools, Microbiotica’s platform enables unrivalled strain-level microbiome analysis linked to patient phenotypes. The Company’s current therapeutic areas of focus are immuno-oncology and IBD and it has established major clinical and academic partnerships in these areas.
Spun out of the Sanger Institute in 2016, the Company is based at Chesterford Research Park near Cambridge, UK. Microbiotica’s investor syndicate includes British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners, and Tencent.
-
-
-
Molten Ventures Plc
-
Stages:that Molten Ventures Plc support
- Venture
-
Sector:that Molten Ventures Plc support
- Health & Social Care
- Information and Communication
- Technology
-
-
-
MVM Partners
-
Stages:that MVM Partners support
- Venture
-
Sector:that MVM Partners support
- Health & Social Care
- Life Sciences
- Technology
-
-
-
Partners beginning with N
-
-
Nauta Capital
-
Stages:that Nauta Capital support
- Venture
-
Sector:that Nauta Capital support
- Technology
About Nauta Capital
Nauta Capital is a pan-European Venture Capital firm investing in early-stage technology companies, with offices in London, Barcelona. and Berlin. With over half a billion assets under management and a team of 24 people, Nauta Capital is one of Europe’s largest B2B focused VCs.
As a sector-agnostic investor, Nauta’s main areas of interest include B2B SaaS solutions with strong network effects, vertically focused enterprise tech transforming large industries as well as those leveraging deep-tech applications to solve challenges faced by large enterprises. Nauta has backed more than 60 companies across Europe and exited 12.
-
-
-
Northern Gritstone
-
Stages:that Northern Gritstone support
- Venture
-
Sector:that Northern Gritstone support
- Life Sciences
- Technology
Northern Gritstone is a ground-breaking new investment company based in the north of England, founded by the Universities of Leeds, Manchester and Sheffield, three of the UK’s leading educational research establishments. It intends to be one of the largest investors into academic spin-outs and IP-rich businesses in the UK dedicated to financing companies in some of the UK’s fastest growing sectors such as advanced materials, energy, health technology and cognitive computation. -
-
-
Notion Capital
-
Stages:that Notion Capital support
- Venture
-
Sector:that Notion Capital support
- Technology
-
-
-
Nucleome Therapeutics
-
Stages:that Nucleome Therapeutics support
- Venture
-
Sector:that Nucleome Therapeutics support
- Life Sciences
About Nucleome Therapeutics
Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The Company has the unique ability to link these variants to gene function and precisely map disease pathways. Nucleome’s cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling the discovery and development of novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Nucleome’s ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford. For more information, please visit nucleome.com.
-
-
-
NVM Private Equity
-
Stages:that NVM Private Equity support
- Venture
-
Sector:that NVM Private Equity support
- Accommodation and Food Service Activities
- Agriculture, Forestry and Fishing
- Arts, Entertainment and Leisure
- Construction
- Consumer Goods & Services
- Education
- Engineering
- Extractives
- Financial and Insurance Services
- Haulage and Logistics
- Health & Social Care
- Information and Communication
- Life Sciences
- Manufacturing
- Professional, Scientific and Technical Activities
- Real Estate Activities
- Technology
- Utilities
- Waste Management
About NVM Private Equity
We are an independent private equity investor focused on lower-mid market businesses across the UK regions.
Founded in 1984 we have almost 40 years’ experience investing into small private regional businesses. Our teams are based in the communities in which they invest which helps to build solid networks and really add value to the teams we back.
Why is that important? Its all down to relationships. Our management teams often tell us that they want to partner with us because of how we work, not simply the capital we can provide. This gives us great access to deals with many investments completed off market.
We help management teams to accelerate growth both organically and through acquisition providing private equity to fund management buy-outs or simply growth capital.
We have built a track record of delivering top quartile returns for the teams that we support and our investors through our Accelerating Value initiatives.
We seek investment opportunities that have the right mix of flair, growth potential and market vision.
-
-
-
Partners beginning with O
-
-
OMass Therapeutics
-
Stages:that OMass Therapeutics support
- Venture Growth
-
Sector:that OMass Therapeutics support
- Life Sciences
About OMass Therapeutics
OMass Therapeutics is a biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. The company’s unique OdyssION™ technology platform comprises novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry. This allows OMass to interrogate not just the target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. The result is cell-system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, therapeutics that target solute carriers, complex-bound proteins, and GPCRs.
Headquartered in Oxford, UK, OMass has raised over $150M (£119M) from a top-tier international investor syndicate, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.
To learn more, please visit www.omass.com. Follow us on LinkedIn and Twitter.
-
-
-
Oxford Quantum Circuits
-
Stages:that Oxford Quantum Circuits support
- Venture
-
Sector:that Oxford Quantum Circuits support
- Technology
About Oxford Quantum Circuits
OQC is Europe’s leading quantum computing company. We bring quantum to our customers’ fingertips and enable them to make breakthrough discoveries. Our quantum computers are available via private cloud and on Amazon Braket.
-
-
-
Oxx
-
Sector:that Oxx support
- Technology
About Oxx
Oxx invests growth capital in European B2B scaleup stage SaaS (Software-as-a-Service) companies with strong commercial traction. With team members in London and Stockholm, Richard Anton and Mikael Johnsson launched Oxx after departing Amadeus Capital in 2017. They are joined by Robert Easton, who was previously head of several Carlyle Group funds, as Senior Adviser. Previous Oxx companies include Forescout (NASDAQ: FSCT), which Richard invested in at Amadeus and continues to manage at Oxx. ForeScout completed its IPO in October 2017.
Oxx’s current portfolio companies are:
-
-
-
Partners beginning with P
-
-
Panoramic Growth Equity
-
Stages:that Panoramic Growth Equity support
- Venture
-
Sector:that Panoramic Growth Equity support
- Other
-
-
-
Paragraf
-
Stages:that Paragraf support
- Venture Growth
-
Sector:that Paragraf support
- Technology
About Paragraf
Based near Cambridge, UK, and building on significant know-how and IP, Paragraf has developed atom-layer-thick two-dimensional materials, with a focus on graphene. Through its growing IP portfolio, Paragraf is applying these materials to a range of advanced medical, electronic and energy devices to benefit society.
-
-
-
Partech
-
Stages:that Partech support
- Venture
-
Sector:that Partech support
- Technology
About Partech
Born in San Francisco and Paris, Partech is one of the most active tech investors in the world, bringing together capital, operational experience, and strategic support for entrepreneurs at seed, venture and growth stages. The current portfolio includes 200+ companies in more than 30 countries, of which 12 are valued at more than $1b: Alan, Bolt, Cazoo, Jellysmack, Made.com, ManoMano, People.ai, Rohlik, Sorare, Toss, Wave, Xendit
-
-
-
Passion Capital
-
Stages:that Passion Capital support
- Venture
-
Sector:that Passion Capital support
- Technology
About Passion Capital
Passion Capital, (@passioncapital) is one of the premier early stage venture capital funds in Europe. Established in 2011 and based in London, the managing partners Eileen Burbidge, Robert Dighero and Stefan Glaenzer have more than 50 years’ collective experience in entrepreneurial, founding and executive operational roles at tech firms. The three of them were personally involved in four of the largest European exits of the year over the last ten years and pride themselves on the strength of their portfolio company founders.
-
-
-
Perspectum
-
Stages:that Perspectum support
- Venture Growth
-
Sector:that Perspectum support
- Life Sciences
About Perspectum
Perspectum, a global medical technology company with offices in the UK, the US, Portugal and Singapore, delivers leading digital technologies that help clinicians provide better care for patients with chronic metabolic diseases, multi-organ pathology, and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers, and technologists, Perspectum offers a way to manage complex health problems at scale. For additional information please visit www.perspectum.com and LinkedIn.
-
-
-
PragmatIC
-
Stages:that PragmatIC support
- Venture Growth
-
Sector:that PragmatIC support
- Technology
About PragmatIC Semiconductor
PragmatIC Semiconductor is a world leader in ultra-low-cost flexible electronics. Its unique technology platform enables innovators to create novel solutions to everyday problems that are beyond the scope of conventional electronics. Its flexible integrated circuits (FlexICs) are thinner than a human hair and extend proven applications such as RFID and NFC into mass market use cases, enabling the potential for trillions of smart objects that can engage with consumers and their environments. PragmatIC is headquartered in Cambridge, UK, with manufacturing operations in the North East.
-
-
-
Prime Ventures
-
Stages:that Prime Ventures support
- Venture Growth
-
Sector:that Prime Ventures support
- Consumer Goods & Services
- Technology
-
-
-
Proximie
-
Stages:that Proximie support
- Venture Growth
-
Sector:that Proximie support
- Life Sciences
About Proximie
Proximie is a global health technology platform focused on digitizing operating and diagnostic rooms. Proximie’s mission is to save lives by sharing the world’s best clinical practice. Every Proximie procedure can be recorded, analysed and leveraged for future use to help inform best practice.
By connecting operating rooms globally, Proximie is creating a rich, insightful data set which naturally feeds best practices into the entire healthcare ecosystem, delivering global connected surgical care.
Founded by Dr Nadine Hachach-Haram, Proximie has now conducted tens of thousands of surgical procedures – in every speciality – and been deployed in over 500 hospitals in across 100 countries in five continents.
Proximie has contracts with over 35 major medical device companies – with access to 90% of operating rooms and diagnostic suites in the UK, US, and EU.
-
-
-
Partners beginning with Q
-
-
Quantexa
-
Stages:that Quantexa support
- Venture Growth
-
Sector:that Quantexa support
- Technology
About Quantexa
Quantexa is a contextual decision intelligence software company that empowers organisations to drive better decisions from their data. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risk and new opportunities by providing a contextual view of internal and external data in a single place. It solves major challenges across financial crime, customer intelligence, credit risk, fraud and throughout the customer lifecycle.
The Quantexa platform enhances performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has over 250 employees and thousands of users working with billions of transactions and data points across the world. It has offices in London, New York, Boston, Belgium, Toronto, Singapore, Melbourne and Sydney.
-
-
-
Quantum Motion
-
Stages:that Quantum Motion support
- Venture Growth
-
Sector:that Quantum Motion support
- Technology
About Quantum Motion
Quantum Motion is developing a revolutionary technology platform; not just a qubit, but a scalable array of qubits based on the ubiquitous silicon technology already used to manufacture the chips in smartphones and computers. The Company is developing fault tolerant quantum computing architectures that are compatible with the CMOS process. Fault tolerant quantum processors will support the most powerful quantum algorithms, targeting solutions to currently intractable problems in fields as diverse as chemistry, medicine and artificial intelligence.
-
-
-
Quell
-
Stages:that Quell support
- Venture Growth
-
Sector:that Quell support
- Life Sciences
-
-
-
Partners beginning with S
-
-
Scottish Equity Partners
-
Stages:that Scottish Equity Partners support
- Venture
-
Sector:that Scottish Equity Partners support
- Information and Communication
- Technology
About Scottish Equity Partners
Scottish Equity Partners (SEP) is a leading UK venture capital firm. Operating from offices in London, Glasgow and Edinburgh, SEP makes equity investments of up to £20m in high growth technology companies.
The new fund will be invested in high-growth companies based mainly in the UK, although investments in other European countries will also be targeted.
-
-
-
Seedcamp
-
Stages:that Seedcamp support
- Venture
-
Sector:that Seedcamp support
- Other
About Seedcamp
Seedcamp is Europe’s seed fund, investing early in world-class founders attacking large, global markets and solving real problems using technology. The Seedcamp Nation includes over 360 breakout businesses and includes the likes of Hopin, Revolut, UiPath, Transferwise, Pointy (acquired by Google), wefox, Ezra, viz.ai and Stupefix (acquired by GoPro). Seedcamp fast-tracks a founder’s vision through immediate access to smart capital, a lifelong community of support and a global network of some of the world’s best talent.
-
-
-
SV Health Investors
-
Stages:that SV Health Investors support
- Venture
-
Sector:that SV Health Investors support
- Life Sciences
About SV Health Investors
SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. SV invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.2B in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 175 companies with more than 75 of these having achieved successful acquisitions or IPOs.
Historically, SV managed funds have been diversified across the three sectors. However, the firm’s seventh vintage of core funds is separated into three distinct vehicles; the SV7 Impact Medicine Fund forms and funds early-stage biotechnology companies developing precision medicines, the Growth Fund accelerates growth-stage healthcare services, medical products and digital health companies and the Medtech Convergence Fund specializes in novel medical device and remote-monitoring technologies.
Alongside their core funds, SV manages the Dementia Discovery Fund, focused on discovering and developing novel therapeutics for dementia, and the International Biotechnology Trust plc, a publicly-traded investment trust.
-
-
-
Partners beginning with T
-
-
Tenpoint Therapeutics
-
Stages:that Tenpoint Therapeutics support
- Venture Growth
-
Sector:that Tenpoint Therapeutics support
- Life Sciences
Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. We are addressing the ultimate cause of vision loss by replacing diseased cells with healthy ones to permanently restore vision. Tenpoint’s global team is united by our passion for science and our commitment to patients.
-
-
-
Thought Machine
-
Stages:that Thought Machine support
- Venture Growth
-
Sector:that Thought Machine support
- Technology
About Thought Machine
Thought Machine was founded in 2014 with a mission to enable banks to deploy modern systems and move away from the legacy IT platforms that plague the banking industry. We do this through our cloud native core banking platform, Vault. This next generation system has been written from scratch as an entirely cloud native platform. It does not contain a single line of code which is legacy, or pre-cloud.
Founded by entrepreneur Paul Taylor, Thought Machine’s customers include Lloyds Banking Group, SEB, Standard Chartered and Atom bank. We are currently a team of more than 350 people spread across offices in London and Singapore.
-
-
-
Partners beginning with U
-
-
UCL Technology Fund
-
Stages:that UCL Technology Fund support
- Venture
-
Sector:that UCL Technology Fund support
- Engineering
- Life Sciences
- Professional, Scientific and Technical Activities
About UCL Technology Fund and UCL Technology Fund 2
The UCL Technology Funds are dedicated to investing in intellectual property and commercialisation opportunities arising from UCL’s world-class research base, focusing in particular on the physical and life sciences. The funds support UCL academics in achieving the full potential of innovations that have prospects for outstanding societal and market impact, right through the development journey from initial proof of concept to practical commercial application.
The Funds are managed by AlbionVC, one of the largest independent venture capital investors in the UK, in collaboration with UCL Business.
-
-
-
Ultraleap
-
Stages:that Ultraleap support
- Venture Growth
-
Sector:that Ultraleap support
- Technology
-
-
-
Partners beginning with W
-
-
Westbridge
-
Stages:that Westbridge support
- Venture
-
Sector:that Westbridge support
- Consumer Goods & Services
- Technology
-
-
-
Partners beginning with 0-9
-
-
13books Capital
-
Sector:that 13books Capital support
- Technology
About 13books Capital
13books Capital invests in tomorrow’s financial technology with a mission to back Europe’s boldest and best fintech founders. Coupled with the experience and knowledge of its extensive network, 13books Capital supports the journey of fintech pioneers to realise their ambitions to scale globally.
-
-
The information has been supplied by each fund manager or company. British Patient Capital makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any such data or information. The information is for information only.
In cases where fund managers have different strategies for different funds, the information refers to the funds to which British Patient Capital has made commitments.
The investment range for funds typically refers to the amount at first investment, not the full amount that may be invested through further funding rounds, or by other investors that may join in a funding round.
For full information see the website terms and conditions.